Key Takeaways for Intuitive Surgical Stock
- Intuitive Surgical reported Q1 2026 revenue of $2.77 billion, a 23% increase year-over-year.
- Operating income reached $860 million in Q1 2026, up 48% year-over-year.
- Operating margins expanded to 31% in Q1 2026, up from 26% in the year-ago quarter.
- TIKR’s model values Intuitive Surgical stock at around $684 by December 2030, implying roughly 70% total return from the current price.
If Intuitive Surgical’s operating leverage is the story, the numbers to watch are all on TIKR. Explore ISRG’s full income statement history on TIKR for free →
Intuitive Surgical Posts 23% Revenue Growth in Q1 2026 as Operating Leverage Accelerates
Intuitive Surgical (ISRG) delivered a standout first quarter in 2026, reporting $2.77 billion in revenue against a market narrative focused almost entirely on competitive headwinds in China and the shadow cast by GLP-1 drugs on bariatrics.
The company behind the da Vinci surgical robot, a platform that enables surgeons to perform complex procedures through tiny incisions using robotic arms controlled from a console, placed 431 da Vinci systems in the quarter.
That was up from 367 systems a year earlier.
Total procedures grew 17%, with da Vinci procedures up 16% to 847,000 and Ion lung biopsy procedures surging 39% to 43,000.
The newer da Vinci 5 platform is running approximately 11% higher utilization than the older Xi system it replaces.
U.S. da Vinci procedures grew 14%, led by general surgery, with after-hours procedure volume up 31% year-over-year.
Recurring revenue, which includes instruments, accessories, and service contracts, accounted for 86% of total Q1 revenue.
CFO Jamie Samath described the model directly: “Revenue growth ahead of total procedure growth reflects, in large part, the differentiated value of da Vinci 5.”
China remained a drag, with system placements of just 4 units in the quarter and procedure growth running below the corporate average.
Bariatric procedures in the U.S. declined approximately 10%, a direct consequence of GLP-1 adoption.
Management raised its full-year da Vinci procedure growth forecast to a range of 13.5% to 15.5%.
The transcript explains what drove growth. The income statement explains how that growth is translating into profit. Pull up ISRG’s financials on TIKR and see the margin story for yourself, for free →
Intuitive Surgical’s Operating Expenses Grew 10% While Revenue Grew 23%: The Leverage Is Here
Intuitive Surgical’s revenue reached $2.77 billion in Q1 2026, up 23% year-over-year.
Gross margins came in at 66%, compared to 65% in the year-ago quarter, reflecting product cost reductions and fixed overhead leverage.
Total operating expenses were $980 million in Q1 2026.
That figure grew only 10% year-over-year, less than half the rate of revenue growth.
The gap between 23% revenue growth and 10% opex growth is the operating leverage mechanism: the same cost base is serving a materially larger revenue base.
Operating income reached $860 million in Q1 2026, up 48% year-over-year.
Operating margins expanded to 31%, up from 26% in Q1 2025.
Samath also confirmed the driver: “Non-GAAP operating margin was strong at 39%, primarily reflecting leverage of fixed costs.”
The da Vinci 5 contribution margin is now comparable to the legacy Xi system, eliminating the dilution that weighed on margins during the new platform’s ramp.
The income statement is not reflecting analyst concerns about China or GLP-1s, it is reflecting what happens when a high-fixed-cost platform scales at 23% annually while holding opex growth to single digits
Intuitive Surgical Leads MDT and SYK on Operating Margins by 9 to 13 Points, and the Gap Is Widening
Intuitive Surgical’s operating margin reached 31% in Q1 2026, a level Medtronic (MDT) and Stryker (SYK) have not come close to matching across the same eight-quarter window.
Medtronic posted an operating margin of 18% in the most recent quarter, the lowest reading in the comparison set and down from 22% just two quarters prior.
Stryker reached 18% as well in Q1 2026, a sharp compression from 27% in Q4 2025.
The spread between Intuitive Surgical and its two closest medtech peers now sits at 13 points against Medtronic and 13 points against Stryker.
Intuitive’s margin has held above 28% in every quarter shown, never dipping below that floor even as peers cycled through compression and partial recovery.
The operating leverage mechanism in the income statement — revenue growing at more than twice the rate of opex — is what keeps that floor elevated and explains why the gap to peers is structural rather than cyclical..
TIKR’s $684 Target on Intuitive Surgical Stock Requires the Operating Leverage to Hold
TIKR’s model values Intuitive Surgical at around $684 by December 2030, implying roughly 70% total return from the current price of around $402, or approximately 12% per year.
For that target to be reached, the operating leverage dynamic visible in Q1 2026 has to sustain: revenue must continue to outpace opex growth as the installed base expands and the da Vinci 5 ecosystem deepens.
The income statement argues that condition is already in place, with opex growth running at less than half the rate of revenue growth for at least the current period.
The TIKR model puts numbers to the thesis. Run your own valuation of ISRG on TIKR for free →
Should You Invest in Intuitive Surgical, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Intuitive Surgical, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ISRG stock on TIKR for Free →
What Did Intuitive Surgical Say About China in Q1 2026?
Management said China procedure growth ran below the corporate average in Q1 2026, with only 4 system placements in the quarter, and does not expect clarity on potential new reimbursement policies until 2027.
